Background: Activated circulating endothelial cells (aCECs) have been indicated as a potential biomarker for cancerous angiogenesis in varieties of malignancies. Furthermore, several studies have exhibited aCECs were related with progression-free survival (PFS) and overall survival (OS) in anti-angiogenesis therapy. Anlotinib is a TKI of VEGFR1/2/3, FGFR1-4, PDGFR a/b, and c-Kit. As a third-line and above treatment on advanced NSCLC, Anlotinib has shown an affirmatory efficacy in ALTER0303 controlled trial. Herein we investigated the connection between aCECs and PFS, OS and metastases burden in the trial. Method: Blood samples were collected at baseline (pre-therapeutically), the 7th, 15th, 21th, 42nd, 63rd day of Anlotinib or placebo. aCECs was measured by Flow Cytometry. Receiver-operating characteristics (ROC) analysis was used to determine a cutoff value of baseline aCECs counts to divide them into high and low groups. The predicting value of aCECs for PFS was investigated by univariate survival analysis. Chi-square test for baseline aCECs counts and patients' clinical characteristics before Anlotinib or placebo treatment was performed. Result: aCECs were obtained in 78 patients (Anlotinib n¼49). No significant difference in baseline characteristics was found between two arms (P>0.05). High baseline aCECs count was statistically in connection with more metastatic lesions (>3) (c 2 ¼ 4.905,P¼0.027). 49 Anlotinib treated patients were divided into 35 and 14 according to the ratio of minimal aCECs counts at every time point and baseline (aCECs min/baseline), as <1 and 1. Median follow-up was 8.6 months. Patients with min/baseline<1 had longer median PFS than ones with min/baseline>1 (193 vs.124 days, HR¼0.439, 95%CI 0.211-0.912, P¼0.023. shown in Table1). However, no significant relation between PFS and aCECs min/baseline was found in control arm. Conclusion: Decreased aCECs during an initial period of Anlotinib therapy may predict longer PFS and baseline aCECs count may be related with the number of metastatic lesions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.